FDA Brief

Warning letters Devices

FDA warning letter to

Linemaster Switch Corporation

High riskIssued May 27Posted Jul 22Center for Devices and Radiological Health

Linemaster Switch Corporation, a Connecticut maker of foot pedals for medical lasers, was cited for quality system failures after an FDA inspection.

What happened

FDA inspected Linemaster Switch Corporation in Woodstock, CT from February 4, 2026 through March 6, 2026 and found the company's quality management system did not meet the Quality Management System Regulation (21 CFR Part 820), which makes the devices adulterated. The investigator found undocumented rework of mis-torqued foot pedals, no risk analysis for one pedal used with Class IV lasers, a customer complaint about calibration failures closed without investigation, and calibration software and firmware that were never properly validated. The company responded on March 30, 2026, but FDA said it could not judge the response adequate because no timelines or revised documents were provided.

What FDA found

  1. Foot pedals that failed calibration were reworked (screws torqued and units recalibrated) without the rework records their own procedure requires.

    ISO 13485:2016, Clause 8.3.4 (21 CFR Part 820)
  2. The company had no risk analysis (process FMEA) for a foot pedal used to control Class IV lasers, and its risk management procedure does not say how risk work is done, approved, updated, or how complaints feed into it.

    ISO 13485:2016, Clause 7.1
  3. A customer corrective action request about 6 foot pedals that failed calibration at the customer's site was never investigated; the root cause was left blank and the corrective action marked "NA".

    ISO 13485:2016, Clause 8.5.2
  4. The company has no procedures or controls to monitor temperature in the work environment, even though it knew since 2013 that temperature swings cause its sensor output to drift.

    ISO 13485:2016, Clause 6.4.1
  5. The software used to calibrate and test foot pedals was not adequately validated: no raw data, pass/fail criteria, or sample size rationale, routine software COM port errors were not investigated, and units that passed in-house testing later failed at the customer.

    ISO 13485:2016, Clause 7.6
  6. The firmware change meant to stop calibration drift was not validated across temperatures, with no data linking temperature to sensor output.

    ISO 13485:2016, Clause 7.6

What FDA wants

FDA asks the company to reply in writing within 15 business days with the specific steps taken, revised procedures, completed retrospective reviews, validation documents, and a timetable for anything not yet finished. FDA also says a follow-up inspection will be required.

Who should pay attention

  • hospitals and clinics that use Class IV medical lasers with these foot pedals
  • device brands that buy foot pedal accessories from this manufacturer
  • distributors and servicers of laser device accessories

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. RDM Express Inc.

    FDA says RDM Express made ready-to-eat fermented cabbage under insanitary conditions and without adequate pathogen controls.

    High risk
  2. Unilam Co., LTD

    Unilam Co., LTD's UV sunlamps violate quality-system and radiation-safety testing rules, FDA says.

    High risk
  3. Curia New York, Inc.

    FDA warned Curia New York's Rensselaer, New York API plant that undocumented lab injections, shredded records and shared passwords violate CGMP.

    High risk
  4. Nipro Renal Solutions USA, Corporation

    Nipro Renal Solutions USA released hemodialysis dialysate lots with out-of-spec endotoxin (bacterial toxin) and had widespread quality-system failures, FDA says.

    High risk